Literature DB >> 7572355

Human thymidine kinase 1. Regulation in normal and malignant cells.

B Munch-Petersen1, L Cloos, H K Jensen, G Tyrsted.   

Abstract

In mammalian cells, salvage pathway phosphorylation of thymidine is catalyzed by two thymidine kinases: the cell-cycle regulated cytoplasmic TK1 and the constitutively expressed mitochondrial TK2. Since TK1 is virtually absent in non-dividing cells, TK2 is probably the only thymidine kinase present in these cells. In cellular metabolism, TK1 and TK2 presumably serve to maintain sufficient dTTP for DNA replication and repair. TK1 purified from phytohemagglutinin-stimulated human lymphocytes is a dimer in the absence and a tetramer in the presence of ATP. In addition to the molecular weight transition, incubation with ATP at 4 degrees C or storage with ATP induces a reversible, enzyme concentration-dependent, kinetically slow transition from a low to a high affinity form of TK1, with Km values of 14 microM and 0.5 microM, respectively. This affinity difference implies that at cellular thymidine concentrations, the difference in catalytic activity between the two TK1 forms will be 3-5-fold. Calculations of cellular TK1 concentration suggested that the low affinity dimer form was dominant in G0/G1 cells and the high affinity tetramer form in S-phase cells. Hence, the transition may serve to fine-tune the cell-cycle regulation of thymidine kinase activity on the post-translational level. To study the ATP effect on the molecular level, an IPTG inducible T7 RNA polymerase-dependent expression system for the entire human TK1 polypeptide in E. coli was established. The recombinant TK1 has the same subunit mass and specific activity as the native enzyme. However, the recombinant TK1 solely displayed the kinetics of the high affinity form, with Km values of 0.3-0.4 microM regardless of pre-exposure to ATP, indicating that the ATP effect may be dependent on post-translational modifications absent in E. coli. Surprisingly, we did not observe any effect of ATP on TK1 purified from bone-marrow cells from a patient with acute monocytic leukemia (AMOL). Furthermore, the Km values of TK1 from these cells were 45 microM for the ATP-free enzyme and 65 microM for the ATP-incubated enzyme. With TK1 purified from HL-60 cells, we obtained the same pattern and kinetic values as for TK1 from lymphocytes. In the light of the results with the recombinant TK1, we presume that the lack of ATP effect and very high Km values observed for the AMOL TK1 may be due to changes in post-translational regulatory mechanisms in acute monocytic cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572355     DOI: 10.1016/0065-2571(94)00014-t

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN: 0065-2571


  41 in total

1.  A novel in vitro assay to assess phosphorylation of 3'-[(18)F]fluoro-3'-deoxythymidine.

Authors:  Ning Guo; Jingping Xie; H Charles Manning; Natasha G Deane; M Sib Ansari; Robert J Coffey; John Gore; Ronald R Price; Ronald M Baldwin; J Oliver McIntyre
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

Review 2.  Development of radiotracers for oncology--the interface with pharmacology.

Authors:  Rohini Sharma; Eric Aboagye
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

3.  A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.

Authors:  Lale Kostakoglu; Fenghai Duan; Michael O Idowu; Paul R Jolles; Harry D Bear; Mark Muzi; Jean Cormack; John P Muzi; Daniel A Pryma; Jennifer M Specht; Linda Hovanessian-Larsen; John Miliziano; Sharon Mallett; Anthony F Shields; David A Mankoff
Journal:  J Nucl Med       Date:  2015-09-10       Impact factor: 10.057

Review 4.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

5.  Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?

Authors:  Sven N Reske; Sandra Deisenhofer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

6.  Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.

Authors:  Seung Jin Lee; Jeong Seok Yeo; Haeng Jung Lee; Eun Jung Lee; Seog Young Kim; Se Jin Jang; Jong Jin Lee; Jin-Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

Review 7.  The emerging role of positron emission tomography in hepatocellular carcinoma.

Authors:  Suraiya R Dubash; Oluwagbemiga A Idowu; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-04-27

8.  Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.

Authors:  Reiko Kameyama; Yuka Yamamoto; Kunihiko Izuishi; Ryusuke Takebayashi; Masanobu Hagiike; Makiko Murota; Masato Kaji; Reiji Haba; Yoshihiro Nishiyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-05       Impact factor: 9.236

9.  Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.

Authors:  Mette Munk Jensen; Kamille Dumong Erichsen; Fredrik Björkling; Jacob Madsen; Peter Buhl Jensen; Liselotte Højgaard; Maxwell Sehested; Andreas Kjær
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

10.  Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer.

Authors:  Lena Carlsson; Anders Larsson; Henrik Lindman
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.